EUDA Health Holdings Ltd美股招股说明书(2026-01-13版)

EUDA HEALTH HOLDINGS LIMITED Convertible Warrant Up to 2,000,000 Ordinary Shares issuable upon exercise of the Warrant Pursuant to a Securities Purchase Agreement dated November 26, 2025 (the “Purchase Agreement”) between us andStreeterville Capital, LLC, a Utah limited liability company and an accredited investor (the “Investor”), we sold to Investor a warrant(the “Warrant”) exercisable into 2,000,000 newly-issued ordinary shares, no par value each, of the Company (the “Warrant Shares”)for an aggregate purchase price of $100,000 (before fees and expenses). Pursuant to our prospectus dated November 4, 2024 (the“Base Prospectus), we filed a prospectus supplement on December 4, 2025 (the “Prospectus Supplement”) for the Warrant Shares andanother prospectus supplement on December 19, 2025 (the “Supplement No. 3”) to reflect a Warrant Amendment dated December 16,2025, pursuant to which (i) the exercise price of the Warrant was reduced from the initial $6.00 per share to $4.00 per share; and (ii)the minimum closing price of the Company’s ordinary shares on Nasdaq required for a “Forced Exercise” (defined below) wasreduced from $7.50 to $6.00. As of the date of this prospectus amendment (the “Supplement No. 4), the Warrant has not beenexercised and no Warrant Share has been issued. On January 13, 2026, the Company and Investor entered into a Second Warrant Amendment pursuant to which parties haveagreed to (i) further reduce the exercise price of the Warrant from $4.00 per share to $2.00 per share; and (ii) further reduce theminimum closing price of the Company’s ordinary shares on Nasdaq required for a “Forced Exercise” (defined below) from $6.00 to$3.00. This Supplement No. 4 is being filed to update and supplement certain information contained in the Prospectus Supplement toreflect these changes to the terms of the Warrant. Each of the Base Prospectus, the Prospectus Supplement, Supplement No. 3 andSupplement No. 4 forms a part of a registration statement (the “Registration Statement”) on Form F-3, as amended (File No. 333-282723) which was declared effective by the Securities and Exchange Commission (the “SEC”) on November 4, 2024. ThisSupplement No. 4 may not be delivered or utilized except in combination with the Registration Statement and the Base Prospectus,including any amendments or supplements thereto. This Supplement No. 4 should be read in conjunction with the RegistrationStatement, the Base Prospectus, the Prospectus Supplement and Amendment No. 3 and if there is any inconsistency between theinformation in the Registration Statement, Base Prospectus, Prospectus Supplement or Supplement No. 3 and this Supplement No. 4,you should rely on the information in this Supplement No. 4. Our ordinary shares are listed on the NASDAQ Capital Market under the symbol “EUDA”. On January 12, 2026, the closingprice of our ordinary shares on the Nasdaq Capital Market was US$2.44. There is no established trading market for the Warrant, and we do not expect a market to develop. In addition, we do notintend to apply for the listing of the Warrant on any national securities exchange or other trading market. Unless otherwise indicated in this prospectus supplement or the context otherwise requires, all references to “we”, “us”, “our”, “theCompany”, and “EUDA” refer to EUDA Health Holdings Limited and its subsidiaries. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possessionor distribution of this Supplement No. 4 or the accompanying prospectus in that jurisdiction. Persons who come intopossession of this Supplement No. 4 or the accompanying prospectus in jurisdictions outside the United States are required toinform themselves about, and to observe any restrictions as to, this offering and the distribution of this Supplement No. 4 andthe accompanying prospectus applicable to that jurisdiction. The date of this prospectus supplement is January 13, 2026 EXPLANATORY NOTE This Supplement No. 4 is being filed solely to update and supplement certain information included in the ProspectusSupplement with certain information set forth below. If there is any inconsistency between the information in the RegistrationStatement, Base Prospectus, Prospectus Supplement or Supplement No. 3 and this Supplement No. 4, you should rely on theinformation in this Supplement No. 4. Capitalized terms that are used but not defined in this Supplement No. 4 are defined in theProspectus Supplement. Warrant Amendment On January 13, 2026, the Company and Investor entered into a Second Warrant Amendment pursuant to which the partieshave agreed to (i) further reduce the exercise price of